181 related articles for article (PubMed ID: 10091804)
41. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Lilenbaum RC; Ratain MJ; Miller AA; Hargis JB; Hollis DR; Rosner GL; O'Brien SM; Brewster L; Green MR; Schilsky RL
J Clin Oncol; 1995 Sep; 13(9):2230-7. PubMed ID: 7545219
[TBL] [Abstract][Full Text] [Related]
42. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
43. Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors.
Dunphy FR; Dunleavy TL; Harrison BR; Cantrell CL; Visconti JL; Pincus SM; Richart JM; Petruska PJ
Ann Oncol; 2001 Apr; 12(4):549-55. PubMed ID: 11398891
[TBL] [Abstract][Full Text] [Related]
44. Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer.
Creaven PJ; Raghavan D; Pendyala L; Loewen G; Kindler HL; Berghorn EJ
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-138-S12-143. PubMed ID: 9331139
[TBL] [Abstract][Full Text] [Related]
45. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
Schilder RJ; Gallo JM; Millenson MM; Bookman MA; Weiner LM; Rogatko A; Rogers B; Padavic-Shallers K; Boente M; Rosenblum N; Adams AL; Ciccotto S; Ozols RF
J Clin Oncol; 2001 Feb; 19(4):1183-94. PubMed ID: 11181685
[TBL] [Abstract][Full Text] [Related]
46. A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.
Jones SF; Infante JR; Thompson DS; Mohyuddin A; Bendell JC; Yardley DA; Burris HA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):471-5. PubMed ID: 22851205
[TBL] [Abstract][Full Text] [Related]
47. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
[TBL] [Abstract][Full Text] [Related]
48. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
49. Phase I trial of paclitaxel/carboplatin in advanced carcinoma of the urothelium.
Vaughn DJ; Malkowicz SB; Zoltick B; Ramchandani P; Tonkonow B; Armstead B; Wein A
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-47-S2-50. PubMed ID: 9045337
[TBL] [Abstract][Full Text] [Related]
50. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
[TBL] [Abstract][Full Text] [Related]
51. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
52. Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony-stimulating factor on a biweekly schedule.
Garcia AA; Parimoo D; Dimery I; Rogers M; Jeffers S; Muggia FM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-62-S19-66. PubMed ID: 9427269
[TBL] [Abstract][Full Text] [Related]
53. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ
J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
[TBL] [Abstract][Full Text] [Related]
54. Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
Kennedy MJ; Zahurak ML; Donehower RC; Noe D; Grochow LB; Sartorius S; Chen TL; Bowling K; Duerr M; Rowinsky EK
Clin Cancer Res; 1998 Feb; 4(2):349-56. PubMed ID: 9516922
[TBL] [Abstract][Full Text] [Related]
55. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors.
Tsao AS; Shin DM; Palmer JL; Lee JS; Glisson BS
Cancer; 2004 May; 100(10):2240-5. PubMed ID: 15139070
[TBL] [Abstract][Full Text] [Related]
56. Phase I-II study of dose intensified chemotherapy with filgrastim and thymopentin in patients with advanced cancer.
Recchia F; De Filippis S; Ginaldi L; Quaglino D; Gulino A; Frati L; Rea S
Clin Ter; 1997; 148(5-6):201-7. PubMed ID: 9377855
[TBL] [Abstract][Full Text] [Related]
57. Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study.
Calvert AH; Lind MJ; Ghazal-Aswad S; Gumbrell L; Millward MJ; Bailey NP; Doré-Green F; Chapman F; Simmons D; Proctor M
Semin Oncol; 1994 Oct; 21(5 Suppl 12):1-6. PubMed ID: 7527590
[TBL] [Abstract][Full Text] [Related]
58. Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies.
Hanna NH; Gordon MS; Fife K; Sandler AB
Am J Clin Oncol; 2002 Aug; 25(4):337-9. PubMed ID: 12151959
[TBL] [Abstract][Full Text] [Related]
59. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
Scarfone G
Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
[TBL] [Abstract][Full Text] [Related]
60. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
Pipas JM; Meyer LP; Rhodes CH; Cromwell LD; McDonnell CE; Kingman LS; Rigas JR; Fadul CE
J Neurooncol; 2005 Feb; 71(3):301-5. PubMed ID: 15735921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
